Related Experiment Videos
Analytical considerations in the development of protein purification processes
1Genentech, Inc., South San Francisco, California.
Bioprocess Technology
|January 1, 1994
Summary
Analytical methods are crucial for successful process development, ensuring product quality and facilitating optimization. Utilizing a range of assays from early-stage monitoring to final characterization guarantees a robust and timely project outcome.
Area of Science:
- Biopharmaceutical Process Development
- Analytical Chemistry
- Quality Control
Background:
- Rapid process development necessitates appropriate analytical methods throughout the entire development cycle.
- Analytical methods are vital for confirming product identity, potency, and purity, while also aiding process optimization.
- Early-stage assays must be robust and applicable to crude samples for effective yield and impurity monitoring.
Purpose of the Study:
- To highlight the importance of selecting suitable analytical methods for efficient biopharmaceutical process development.
- To demonstrate how different analytical techniques support various stages of the development cycle.
- To emphasize the role of validated, complementary methods in ensuring project success.
Main Methods:
- Utilizing robust assays like SDS-PAGE, IEF, and immunoassays for early-stage monitoring of yield and impurities.
- Employing biological assays to track specific activity and detect activity loss during process steps.
- Implementing sophisticated methods such as RP-HPLC and mass spectrometry for late-stage variant characterization.
- Developing process-specific assays, including host cell impurity ELISAs, for targeted monitoring and final product assessment.
Main Results:
- Early-stage methods (SDS-PAGE, IEF, immunoassays) effectively monitor yield and broad impurity removal in crude samples.
- Biological assays successfully track target protein specific activity, identifying detrimental process steps.
- Advanced methods (RP-HPLC, mass spectrometry) characterize product variants at the end of the recovery process.
- Process-specific assays (host cell impurity ELISAs) are developed for precise monitoring and final characterization.
Conclusions:
- The strategic selection and validation of complementary analytical methods are essential for timely and successful biopharmaceutical process development.
- A combination of robust early-stage assays and sophisticated late-stage characterization methods ensures comprehensive process understanding and product quality.
- Well-validated analytical methods provide assurance throughout the development lifecycle, from initial recovery to final product release.